Sort   by:  
 Page size 
UnknownHydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Not available
S-EPMC6269131 | biostudies-literature
UnknownSIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Not available
S-EPMC6553796 | biostudies-literature
ProteomicsInvestigating the proteome of red blood cells and reticulocytes in Polycythemia Vera and Essential Thrombocythemia
The project aims at comparing the effect of the JAK2V617F mutation on protein expression in human erythroid cells in the context of Polycythemia Vera and Essential Thrombocythemia
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD029965 | Pride
Reticulocytes Human red blood cells Erythrocytes Polycythemia vera Nlc-ms/ms Orbitrap fusion Essential thrombocythemia Jak2v617f 
UnknownEfficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Not available
S-EPMC8316412 | biostudies-literature
UnknownSingle-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.
Not available
S-EPMC9092407 | biostudies-literature
UnknownEfficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Not available
S-EPMC3586170 | biostudies-literature
UnknownRare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.
Not available
S-EPMC7099330 | biostudies-literature
UnknownTreatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
Not available
S-EPMC5777190 | biostudies-literature
UnknownCombination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Not available
S-EPMC3971078 | biostudies-literature
UnknownEvent-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Not available
S-EPMC10539163 | biostudies-literature
Sort   by:  
 Page size